Growing GLP-1 adoption could put $30 billion to $55 billion in annual food and beverage industry sales at risk by 2030, as appetite-suppressing medications reshape consumer eating habits.

Growing GLP-1 adoption could put $30 billion to $55 billion in annual food and beverage industry sales at risk by 2030, as appetite-suppressing medications reshape consumer eating habits. 

The GLP-1 reckoning is reshaping the global food and beverage industry, with the widespread adoption of GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro estimated to put $30 billion to $55 billion in annual food market sales at risk by 2030. As appetite-suppressing GLP-1 medications curb consumer cravings and "food noise," categories like snacks, sugary beverages, and frozen foods face mounting disruption, while high-protein, fresh, and portion-controlled foods emerge as clear winners. This shift marks one of the most significant demand-side disruptions to hit the food and beverage industry in decades, forcing CPG brands, grocers, and restaurants to rethink product strategy for the GLP-1 era.

Glucagon-like peptide-1 (GLP-1) receptor agonists — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and a fast-growing pipeline of oral candidates — have moved from a diabetes therapy into one of the most consequential forces reshaping household food spending in decades. By suppressing appetite and reducing "food noise," the constant background craving for the next snack or drink that powered much of the modern packaged food and beverage industry, these drugs are structurally shrinking and reshaping grocery baskets, restaurant visits, and beverage consumption for tens of millions of households.
Adoption has moved quickly. Roughly one in five U.S. households now includes a current GLP-1 user, more than double the share from early 2025, and industry researchers project that GLP-1 households could account for over a third of all U.S. food and beverage units sold by 2030. Users report consuming meaningfully fewer calories per day and cutting grocery spending by anywhere from 5% to over 30% depending on the study and household income band, with the reduction most pronounced in the first six to twelve months of treatment. Its estimated that GLP-1 adoption could remove USD 30-55 billion in annual food and beverage industry revenue by 2030, while other analysts describe a smaller but still material multi-billion-dollar drag building steadily through 2032 as oral formulations and expanded insurance coverage widen the eligible population.
Because the effect is not uniform — some categories are being hollowed out while others are growing briskly on the back of the same consumer trend — a single "food and beverage" growth or decline number obscures more than it reveals. The segmentation below groups food and beverage categories specifically by how GLP-1 adoption is displacing demand within the category, rather than by traditional product or channel definitions.
Food & Beverage Market Segmentation by Displacement Category
Severe Contraction
These categories depend heavily on the impulse-driven, high-calorie consumption that GLP-1 drugs directly suppress, and show the sharpest, most consistent declines across independent studies.

• Salty snacks: Spending on savory snacks such as chips has dropped by roughly 10% within six months of a household member starting treatment, and the category is repeatedly named among the most exposed.
• Sweets, confectionery, and baked goods: Cookies, candy, chocolate, and sweet bakery items show similarly steep declines; 61% of current GLP-1 users report buying fewer sweet treats.
• Sugary soft drinks and juices: Non-alcoholic sugary beverages are contracting consistently across studies, with roughly one in five users stopping sugary drink purchases entirely.
• Frozen foods: Frozen food shows the single largest category-level dollar-spend decline of any grocery segment tracked in year-one GLP-1 use, per FTI Consulting analysis.
• Alcohol: Around 20% of users report reduced alcohol consumption, with cumulative U.S. alcohol volume projected to fall roughly 2.5% through 2035 due to GLP-1 adoption; unlike food, alcohol has few reformulation levers since its core product is inherently caloric.
• Fast food and coffee-shop dinner/breakfast occasions: Dinner traffic at fast-food chains has fallen an estimated 6% among regular users, and high-income users in particular are cutting sugary coffee drinks and pastries at breakfast.
• Pantry staples: Categories like pasta, dairy staples, and condiments are down more than 10% among long-term GLP-1 households versus comparable non-users, signaling a broader move away from traditional multi-course meal formats (dry beans and grains are a notable exception, holding up as an affordable, high-satiety staple).

Moderate / Mixed Disruption
These categories show real but uneven effects — some sub-segments decline while others within the same category hold steady or benefit from premiumization and reformulation.

• Casual dining and full-service restaurants: Overall restaurant spending among GLP-1 users has in some data sets actually increased, as households seek convenient, portion-appropriate options rather than cooking multiple separate meals — even as fast-food dinner traffic specifically declines. Operators offering smaller portions, protein-forward menu items, and split-plate pricing are seeing the least disruption.
• Red meat and beef: Beef consumption is declining among GLP-1 users even as other proteins gain, making this one of the few protein sub-categories facing headwinds rather than tailwinds.
• Impulse checkout items (gum, small candy): These call for re-merchandising rather than outright volume loss, as the category is more exposed to store layout and placement than to caloric substitution per se.
• Oils and fats: The picture is less clear-cut than sugar or refined carbohydrates; saturated fat purchases decline modestly, but total fat consumption changes are smaller in magnitude than shifts seen in sugar and snack categories.
• Branded "Ozempic-friendly" convenience meals: A fast-growing sub-segment of ready-to-eat and reformulated products marketed directly at GLP-1 users, though some nutrition experts caution this risks becoming a health "halo" for products that remain highly processed.

Resilient / Growth Categories
These categories are structurally benefiting from GLP-1 adoption, either because they align with the nutritional needs of users on therapy (particularly the need to preserve lean muscle mass, since 20-40% of weight lost on GLP-1s can come from muscle) or because they meet demand for portion control and satiety.

• Fresh produce: Consistently one of the strongest gainers — 44-55% of users report buying more fresh produce, driven by fiber content and whole-food positioning that aligns with clinical guidance for patients on therapy.
• Fresh and lean protein (chicken, fish, seafood): Fresh chicken and seafood purchases are up sharply (some studies show 15-31% increases), as users prioritize high-protein, lower-calorie-density options over red and processed meat.
• High-protein dairy and yogurt: Greek yogurt and similar high-protein dairy products are among the most consistent winners, with sales growth in the high single digits.
• Nutrition bars, protein snacks, and jerky: Portion-controlled, protein-forward snack formats are directly benefiting from "snackification" migrating toward smaller, more frequent, nutrient-dense eating occasions; jerky and nutrition-bar sales have both shown mid-single-digit-plus growth.
• Functional and low-/no-sugar beverages: Water, electrolyte and hydration drinks, and lower-sugar carbonated beverages are gaining as users seek hydration and flavor without "empty" calories; energy drinks in particular have shown notable growth among this cohort.
• Deli and portion-controlled prepared foods: Deli items are gaining favor because they offer better portion control than family-sized packaged alternatives that GLP-1 users may struggle to finish before spoilage.
• Supplements and wellness-adjacent nutrition: Vitamins and nutritional supplements are seeing increased purchase rates as users build out self-directed regimens to support their treatment, an area many researchers describe as still under-served by structured product offerings.

Outlook Through 2032
The direction of food and beverage disruption through 2032 will likely deepen along the same lines already visible today rather than reverse. As oral GLP-1 formulations roll out more broadly and insurance coverage expands the eligible population well beyond today's roughly one-in-five U.S. households, the categories in severe contraction — snacks, sweets, sugary drinks, frozen foods, and alcohol — face a sustained structural headwind rather than a temporary dip, since food noise reduction removes the behavioral trigger these categories were built to monetize. At the same time, growth categories tied to protein, fiber, and portion control are likely to keep expanding as manufacturers reformulate, resize, and remarket around this cohort.
Two dynamics will complicate simple extrapolation. First, churn: a meaningful share of users cycle on and off GLP-1 therapy, and roughly half of those who stop are likely to restart, meaning demand for indulgent categories doesn't disappear so much as become more volatile and harder to forecast on typical planning cycles. Second, "premiumization": several severely contracting categories are seeing unit and volume declines even as dollar spend holds up, implying consumers are eating less but trading up in quality — a nuance that will separate winners from losers within categories that look uniformly troubled on a top-line basis. Food and beverage companies planning through 2032 should segment their own portfolios against this displacement framework category by category, rather than treating "GLP-1 exposure" as a single uniform risk factor.